Curative Biotech announces Canadian patent allowance

1 week ago 8

TipRanks

Sat, January 24, 2026 astatine 7:50 AM CST 1 min read

Curative Biotech (CUBT)nology announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian Patent Application No. 3,151,011, entitled “Druggable Target to Treat Retinal Degeneration.” Curative is the exclusive worldwide licensee of this exertion pursuant to a patent licence statement with the National Eye Institute, portion of the National Institutes of Health. The invention, developed nether the enactment of Dr. Kapil Bharti and his squad astatine the NEI, identifies a caller pharmacological people with imaginable relevance to the progression of retinal degenerative diseases. The Canadian patent includes 22 allowed claims, including claims directed toward topical ocular transportation approaches applicable to metformin-based formulations, which align with the Company’s intended way of administration. The patent is expected to formally contented successful the coming months.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Disclaimer & DisclosureReport an Issue

Read Entire Article